Philips and Elekta Deepen Strategic Partnership in Precise and Individualized Oncology Care

PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA), and Elekta (EKTA-B.ST) signed agreements to deepen their existing strategic partnership to advance comprehensive and personalized cancer care through precision oncology solutions.

The extended collaboration builds on the two companies’ successful cooperation in the fast-emerging field of magnetic resonance (MR)-guided adaptive radiation therapy. Through deeper cross-portfolio collaboration, Philips and Elekta will utilize their complementary capabilities to further improve patient care.

Benefiting patients throughout the care pathway

Oncology care is transforming, driven by an increasingly precise diagnosis of each tumor, and a continuously expanding range of therapy options. To fully capitalize on these opportunities, healthcare providers require integrated solutions throughout the entire cancer care pathway, from diagnosis to treatment and follow-up.

This integrated approach has the potential to provide:

  • Quicker, more accurate visualization of the tumor
  • Easier decision of optimal treatment strategy
  • Earlier assessment of therapy response
  • More effective and efficient therapy delivery

The strengthened strategic partnership intends to further deliver a superior experience in diagnosis and adaptive, personalized treatments for clinicians, shorter treatment times and more precise therapy for patients, and lowered costs of care for healthcare providers.

"To capitalize on the opportunities presented by increasingly precise diagnosis and the fast-expanding range of therapies available for cancer patients, it's essential to provide integrated systems and solutions that provide the right insights at the right time throughout each patient's care journey," said Kees Wesdorp, Chief Business Leader of Precision Diagnosis at Philips. "By deepening our already-successful collaboration with Elekta, we will accelerate towards our goal of providing clear care pathways and predictable outcomes for every cancer patient. Today's announcement is an important next step in the implementation of our strategy in precision diagnosis."

"I expect this extended partnership to unlock opportunities that will provide better outcomes for people with cancer," said Gustaf Salford, Elekta's President and CEO. "Together, we'll combine advanced informatics and image-guided radiation therapy solutions to deliver greater precision in oncology. This means easier selection by clinicians of the optimal treatment strategy and more efficient and effective therapy delivery."

In this preferred, although non-exclusive, partnership, Elekta and Philips will leverage their capabilities to pursue integrated vendor-agnostic solutions, enhancing interoperability between the two parties' systems and software in order to drive precision in oncology.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 77,000 employees with sales and services in more than 100 countries.

About Elekta

For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to - and benefits from - more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange.

Most Popular Now

AI Predicts Lung Cancer Risk

An artificial intelligence (AI) program accurately predicts the risk that lung nodules detected on screening CT will become cancerous, according to a study published in the journal Radiology. Lung cancer is...

EU Health Policy Platform Calls for Prop…

The European Commission is inviting public health stakeholders to submit initiatives for anew cycle of Thematic Networks under the EU Health Policy Platform. The purpose of a Thematic Network is...

What Next for Social Care?

Highland Marketing's advisory board welcomed Jane Brightman, social care lead at Institute of Health and Social Care Management, to discuss the sector and its technology needs. A lot of hope...

Philips Introduces the New Spectral Comp…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced its newest solution for precision diagnosis with the global introduction of its spectral detector-based Spectral Computed...

Web-Based System Developed to Give Care …

Black Country Pathology Services has worked with CliniSys to create the ICE Portal, a web-based application that makes it easy for care homes, or other community care settings, to be...

Grand Challenge Research Harnesses AI to…

Breast cancer has recently overtaken lung cancer to become the most common cancer globally, according to the World Health Organization. Advancing the fight against breast cancer, the BreastPathQ Challenge was...

UCSF Improves Fetal Heart Defect Detecti…

UC San Francisco researchers have found a way to double doctors' accuracy in detecting the vast majority of complex fetal heart defects in utero - when interventions could either correct...

EU4Health Programme: Regulation (EU) 202…

The Programme should be a means of promoting actions in areas where there is a Union added value that can be demonstrated. Such actions should include, inter alia, strengthening...

MEDICA 2021 + COMPAMED 2021: Medical Tec…

15 - 18 November 2021, Düsseldorf, Germany. The date for the globally leading live platforms for the medical technology industry remains a fixed feature in everybody's calendar this year too. The...

New AI Technology Protects Privacy

Digital medicine is opening up entirely new possibilities. For example, it can detect tumors at an early stage. But the effectiveness of new AI algorithms depends on the quantity and...

GP use of Tech Helps Prevent Prescribing…

Academic analysis shows primary care prescribers have been preventing adverse drug reactions, harm and hospital admissions through safer prescribing, after using prescribing tech. The company behind the system also reveals...